Insider · CIK 0001816838
Adams Catherine Owen
ceoofficerdirector
Files at ACAD (ACADIA PHARMACEUTICALS INC), AGIO (AGIOS PHARMACEUTICALS, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Common stock | +2,120 | $0.00 | $0 | 6,073 | Jun 23, 2025 |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | AGrant or award Restricted stock unitsderivative | +2,816 | $0.00 | $0 | 2,816 | Jun 23, 2025 |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | AGrant or award Stock options (right to buy)derivative | +15,768 | $0.00 | $0 | 15,768 | Jun 23, 2025 |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Restricted stock unitsderivative | -2,120 | $0.00 | $0 | 0 | Jun 23, 2025 |
| Jun 13, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Common stock | +1,977 | $0.00 | $0 | 3,953 | Jun 17, 2025 |
| Jun 13, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Restricted stock unitsderivative | -1,977 | $0.00 | $0 | 1,976 | Jun 17, 2025 |
| Mar 24, 2025 | ACAD ACADIA PHARMACEUTICALS INC | AGrant or award Stock Option (Right to Buy)derivative | +319,976 | $0.00 | $0 | 319,976 | Mar 26, 2025 |
| Mar 24, 2025 | ACAD ACADIA PHARMACEUTICALS INC | AGrant or award Restricted Stock Unitsderivative | +94,039 | $0.00 | $0 | 94,039 | Mar 26, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.